Linked Life Data

21658647

Source:http://linkedlifedata.com/resource/pubmed/id/21658647

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
2011-6-10
pubmed:abstractText
Pulmonary exacerbations represent a key outcome variable in clinical trials of cystic fibrosis (CF). As there is variation in the trigger for use of intravenous antibiotics compared to the use of oral antibiotics or new nebulised therapy for treatment of exacerbations, the consensus view is that use of intravenous antibiotics cannot be regarded as the key defining character for an exacerbation on its own. The consensus view is that the clinical need for additional treatment as indicated by a recent change in clinical parameters provides the best definition of an exacerbation. Which parameters to include as well as the problems associated with the use of scoring systems and symptom clusters are being discussed.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jun
pubmed:issn
1873-5010
pubmed:author
pubmed:copyrightInfo
Copyright © 2011 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.
pubmed:issnType
Electronic
pubmed:volume
10 Suppl 2
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
S79-81
pubmed:meshHeading
pubmed:year
2011
pubmed:articleTitle
Pulmonary exacerbation: towards a definition for use in clinical trials. Report from the EuroCareCF Working Group on outcome parameters in clinical trials.
pubmed:affiliation
Royal Brompton Hospital, Respiratory Medicine, London, UK. D.Bilton@rbht.nhs.uk
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't, Consensus Development Conference